The recent announcement of BlueBirdBio to wind down its European commercialisation efforts due to access and pricing challenges for its gene therapy products has put a new spotlight on the market access and payer environment for advanced therapies in Europe.
In this webinar VCLS market access experts analyse the commercial failures of advanced therapies, discuss key HTA challenges for these products in European markets and how to plan ahead to overcome them.
Access the full webinar replay now
Fill in the form to download the content
Sample of the webinar
Featured Speakers
Gabrielle Nayroles, M.Sc.
Director, Market Access
As a Director in the Market Access team, Gabrielle is responsible for conducting market access analyses and providing recommendations and…
View profile
Emmanuelle Sabbah-Petrover, PhD
Director, Complex Biologics
As Director at Voisin Consulting Life Sciences, Emmanuelle manages projects involving cellular and gene-based medicinal products; from early stages of…
View profile
All our resources 
